A Phase 3 Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts

Inclusion Criteria: * Subjects must have 1 to 6 clearly identifiable common warts located on hands feet limbs, and/or trunk * Each wart must measure 3 to 10 mm in their longest dimension (diameter) on the epidermal plane of the skin at baseline visit, * Each wart must be present for at least 4 weeks at the baseline visit, * Plantar, facial, subungual, and common warts in regions of a pre-existing inflammatory condition are excluded. In addition, other warts (e.g., flat, genital) are excluded. * Male or female subjects 2 years of age or older * Females of childbearing potential who are using a highly effective form of birth control or females of non-childbearing potential * Negative in-office urine pregnancy test at Screening and Baseline * Subjects free of any clinically significant dermatologic disorder in the treatment area * Subjects free of any clinically significant systemic condition which will interfere with the study assessments or increase the risk of AEs * Subjects willing to refrain from using other topical products in the treatment area, or prohibited medications for the duration of the study Exclusion Criteria: * Subjects who have used any wart treatments/therapies, prescription or over-the-counter, as follows: * Salicylic acid, cantharidin, sinecatechins (VeregenTM), simple occlusion (e.g., duct tape), and/or any other over-the-counter wart-removing products in the treatment area within 4 weeks of the Baseline Visit. * Cryotherapy (e.g., treatment…